Following the results of the phase 3 FLAURA trial, osimertinib became the gold-standard therapy for previously untreated EGFR mutation-positive (Ex19del or L858R) advanced NSCLC [34,35]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.